BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Study
Jan 23, 2023
BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, today announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug. According to the update, the study used an industry-standard animal model to compare weight loss in two groups of hamsters. Hamsters administered a mid-sized 0.66mg dose of the NanoAb three hours prior to infection experienced no significant weight loss over the six-day trial, whereas the untreated control group’s weight declined 12% on average, a highly statistically significant difference (p<0.0005). “We continue to be thrilled with the results of this ongoing trial,” said BiondVax’s CEO Amir Reichman. “There is strong market demand for COVID prophylactics as evidenced by AstraZeneca’s reported Q1 through Q3 2022 EVUSHELD revenues of $1.5 billion*. EVUSHELD is currently the only prophylactic COVID medication with FDA approval, under emergency use authorization. Our inhaled NanoAb is designed to be self-administered at the time of choosing to generate rapid protection from COVID illness. In contrast, EVUSHELD must be administered via two separate consecutive intramuscular (‘IM’) injections in a health care setting, and the FDA has confirmed it does not effectively neutralize recent Omicron variants of concern.** Data from our trial indicate that our NanoAb may effectively serve as both a therapeutic and protective prophylactic drug, which further enhances its value proposition.”
To view the full press release, visit https://nnw.fm/ZM06t
About BiondVax Pharmaceuticals Ltd.
BiondVax is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, BiondVax has executed eight clinical trials including a seven-country, 12,400-participant phase 3 trial of its prior vaccine candidate and has built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information, visit the company’s website at www.BiondVax.com.
*https://www.astrazeneca.com/media-centre/press-releases/2022/year-to-date-and-q3-2022-results.html
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork.
More News
Salon owners urge Budget VAT cut as staffing pressures grow
Marcus Perkins, who owns a hair and beauty salon in Brierley Hill, says he is scared for the future.
Healey to shield low-income pensioners from income tax in the Budget
Changes are needed to prevent the full, flat-rate state pension becoming liable for income tax after it rises in April.
Why Some People Are Paying to Make Friends
Apps that match personalities — for a price — have surged in popularity amid a loneliness epidemic.
What is the Budget and what could be in it?
Chancellor John Healey will set out his plans for UK taxes on 28 October.
Healey's Budget needs to sustain the stronger economy through gathering clouds
The economic is positive now but come January things could become trickier for the Labour government
Big, noisy and coming to a town near you - why the data centre backlash is growing
Data centres are the lifeblood of our digital world, but there are growing concerns about their environmental impact. The BBC explores their rise in charts.
Attention, Passengers: High Airfares May Be Here to Stay
Ticket prices jumped after fuel costs spiked because of the war with Iran, but airlines say even an end to the conflict will not bring fares back down quickly.
A Fight Over Felon Voting Prompts a Free Speech Debate
A Minnesota group worried that its opposition could expose it to prosecution under the state’s deceptive-practices law. Its lawsuit could have wide implications for limiting speech around elections.
Noah Adams, Longtime Host of ‘All Things Considered,’ Has Died at 84
A postman’s son from Kentucky, he worked hard to lose his accent but never forgot his Appalachian roots. “The best stories come from west of the Potomac,” he said.
How to Straddle the MAGA Divide
Beth Wilkinson is a Washington lawyer who has thrived representing the Trump administration’s enemies and allies alike. Does she represent a vanishing type?
Audi to Build Factory in Georgia, Trump Says
The Volkswagen division, which imports all its cars from Europe or Mexico, has been hit hard by U.S. tariffs.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.